← Back to Clinical Trials
Recruiting Phase 3 NCT06348576
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Trial Parameters
Condition Hypertension,Essential
Sponsor Addpharma Inc.
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 280
Sex ALL
Min Age 19 Years
Max Age N/A
Start Date 2024-05-20
Completion 2025-02
Interventions
AD-209AD-2091AD-209 Placebo
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Orthostatic hypotension with symptom * Other exclusions applied